Synoligo Biotechnologies Expands Insights into Synthesis
Synoligo Biotechnologies Inc., a leading Contract Research and Development Organization (CRDO), is making waves with the launch of a new 5,000 square foot facility dedicated to high-throughput custom oligonucleotide synthesis. This strategic expansion is a testament to Synoligo's rapid growth trajectory and its unwavering commitment to supporting both the therapeutic and diagnostic sectors.
Growth Since Foundation
Founded recently, Synoligo has quickly gained recognition as a trusted partner in the field of oligonucleotide synthesis. The organization has successfully managed to secure its first production facility mere months after its inception, indicating its robust operational planning and strategic foresight. In its inaugural year, the company did not just meet expectations but exceeded them, shipping countless orders and solidifying its position within the industry.
Commitment to Quality and Efficiency
Chief Executive Officer, Xibo Li, PhD, expressed pride in the company's achievements, stating, "This remarkable achievement demonstrates our commitment to providing the highest quality oligonucleotides with a fast turnaround time to support our customers’ success." The new facility is poised to significantly scale their operations while introducing new services that cater to the nuanced needs of their clients.
Community Focus and Employment Opportunities
In alignment with its values of responsible growth, Synoligo is also keen on contributing to the local economy through stable, long-term employment opportunities. Amid a fluctuating job market, the company is keen to ensure job security for community members, enhancing the region's workforce stability.
Leading the Way in Oligonucleotide Synthesis
Co-Founder and Chief Technology Officer, Baozhong Zhao, PhD, highlighted Synoligo's innovative approach, stating, "Synoligo is leading the way in synthesizing custom oligonucleotides for advanced therapeutic research." The combination of an expert team and state-of-the-art equipment is pivotal for their goal of scaling high-throughput synthesis precisely to meet the intricate demands of diagnostic development.
Advanced Facilities for Superior Quality
This new facility is equipped with controlled manufacturing spaces and advanced quality control labs designed to uphold rigorous efficiency and quality standards. With the capability to produce over 10,000 oligonucleotides daily, Synoligo is set to transform how oligonucleotides are manufactured, meeting both existing and emerging market needs.
About Synoligo Biotechnologies
Headquartered in Morrisville, NC, Synoligo Biotechnologies specializes in the manufacturing of complex, highly modified oligonucleotides for diverse clients across academic research, biotech startups, and large pharmaceutical companies. Renowned for delivering high-quality, cost-effective custom solutions, Synoligo stands out as a leader in oligonucleotide synthesis, aiding various research, diagnostic, and therapeutic applications.
Frequently Asked Questions
What is Synoligo Biotechnologies known for?
Synoligo Biotechnologies is recognized for its expertise in oligonucleotide synthesis, specifically tailored for therapeutic and diagnostic applications.
Where is Synoligo Biotechnologies based?
Synoligo is headquartered in Morrisville, NC, at the heart of the Research Triangle area.
What recent expansion did Synoligo undertake?
The company unveiled a new 5,000 square foot facility to enhance its oligonucleotide synthesis capacity significantly.
What kind of employment opportunities does Synoligo offer?
Synoligo aims to provide stable, long-term employment opportunities to strengthen the local community amidst a volatile job market.
How does Synoligo maintain quality?
Equipped with advanced QC labs and controlled manufacturing spaces, Synoligo adheres to strict quality standards to ensure highly efficient production.
